The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

Amgen announces positive top-line results from phase 3 RUTHERFORD-2 trial of evolocumab (AMG 145) in patients with heterozygous familial hypercholesterolemia (Amgen press release). Claire 31 ...

Amgen has submitted the first Biologics Licence Application (BLA) to the US FDA for a PCSK9 inhibitor. Its drug evolocumab is for the treatment of high cholesterol and is an investigational fully ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Both evolocumab and alirocumab have been reported ... fees and has served as an advisor to Sanofi-Aventis, Genzyme and Amgen Corporation. The authors have no other relevant affiliations or ...